Allogene Therapeutics explores ALPHA3 trial potential for allogeneic CAR T in LBCL treatment
Allogene Therapeutics is advancing its ALPHA3 clinical trial to investigate allogeneic CAR T therapies for large B-cell lymphoma (LBCL). Dr. Zachary Roberts, EVP of R&D and CMO, highlighted the potential of off-the-shelf cell therapy to transform LBCL treatment. The company also recently provided a Q1 report emphasizing its progress in allogeneic CAR T development, demonstrating its commitment to cell therapy advancements.
Earnings call transcript: Allogene Therapeutics Q1 2026 sees mixed results with revenue miss
Allogene Therapeutics reported mixed Q1 2026 results, exceeding EPS expectations at -$0.18 but missing revenue forecasts entirely with $0 reported. The company announced positive interim results for its ALPHA3 trial, showing a 58.3% MRD clearance rate, and extended its cash runway into Q1 2029 through a recent public offering. Despite a post-earnings stock drop, premarket trading showed a slight recovery, reflecting investor confidence in its clinical progress and financial stability.
Number of shareholders of Allogene Therapeutics, Inc. – BOATS:ALLO
This article provides financial information for Allogene Therapeutics, Inc. (BOATS:ALLO), specifically focusing on the number of shareholders. It appears to be a financial data page from TradingView, offering an overview of the company's financials without detailed analysis in the provided content. The page also lists various services and resources available on the TradingView platform.
Citadel affiliates, Kenneth Griffin report stakes in Allogene (ALLO)
A Schedule 13G/A filing indicates that Citadel-related entities and Kenneth Griffin have reported shared beneficial ownership of Allogene Therapeutics (ALLO) common stock. Citadel Advisors LLC, Citadel Advisors Holdings LP, and Citadel GP LLC each report holding 2.4% of outstanding shares, while Kenneth Griffin personally holds 2.8%. These disclosures specify the percentages based on Allogene's 243,777,920 shares outstanding as of March 10, 2026, as per the issuer's Form 10-K.
Lynx1 amends 13G for Allogene Therapeutics (NASDAQ: ALLO) showing 0% stake
Lynx1 Capital Management LP and Weston Nichols have filed an amended Schedule 13G/A for Allogene Therapeutics (NASDAQ: ALLO), reporting a 0% beneficial ownership stake. This administrative amendment indicates that the reporting persons hold 0 shares, categorizing their position as "Ownership of 5 percent or less of a class" and suggesting a purely procedural update with no material change in holdings.
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q1 2026 Earnings Call Transcript
Allogene Therapeutics, Inc. discussed its Q1 2026 earnings, highlighting progress in its SemiCell and ALLO-329 clinical programs. The ALPHA-3 trial for SemiCell in large B cell lymphoma showed promising interim futility analysis results, with significant MRD clearance and a favorable safety profile, making outpatient administration feasible. The ALLO-329 program for autoimmune diseases is efficiently progressing through dose escalation, demonstrating early signs of clinical activity and tolerability even at lower doses. The company also confirmed a strong financial position, extending its cash runway into 2029.
Analysts’ Top Healthcare Picks: Allogene Therapeutics (ALLO), Evommune, Inc. (EVMN)
This article highlights bullish analyst ratings for three healthcare companies: Allogene Therapeutics (ALLO), Evommune, Inc. (EVMN), and Alkermes (ALKS). Analysts from TD Cowen and RBC Capital maintained Buy ratings for these companies, citing strong prospects and setting price targets indicating significant upside potential from current share prices. The consensus for all three stocks is a "Strong Buy."
Allogene Therapeutics Reports First Quarter 2026 Financial Results and Business Update
Allogene Therapeutics announced its Q1 2026 financial results, reporting a net loss of $42.6 million and ending the quarter with $266.9 million in cash. The company provided an update on its clinical programs, including positive interim futility analysis from the ALPHA3 trial for cema-cel in LBCL and ongoing dose escalation in the ALLO-329 RESOLUTION trial for autoimmune disease. Allogene anticipates an interim Event-Free Survival analysis for ALPHA3 in mid-2027 and expects to extend its cash runway into Q1 2029 following a recent public offering.
Allogene Therapeutics Q1 Net Loss Narrows
NULL
Allogene Therapeutics - Enters Termination Agreement With Overland Therapeutics On May 12, 2026 - SEC Filing
Allogene Therapeutics has entered into a termination agreement with Overland Therapeutics, effective May 12, 2026. This information was disclosed via an SEC filing.
Earnings Flash (ALLO) Allogene Therapeutics Posts Q1 Loss $0.18, vs. FactSet Est of $0.19 Loss
Allogene Therapeutics (ALLO) reported a Q1 loss of $0.18 per share, which was better than the FactSet estimate of a $0.19 loss. The biotechnology company focuses on developing allogeneic T cell product candidates for cancer and autoimmune diseases, with key programs in Large B-Cell Lymphoma, Autoimmune Disease, and Renal Cell Carcinoma. The article also mentions recent clinical trial expansions and public stock offerings for the company.
Allogene (NASDAQ: ALLO) posts Q1 2026 loss, updates ALPHA3 data and cash runway
Allogene Therapeutics (NASDAQ: ALLO) reported a Q1 2026 net loss of $42.6 million, or $0.18 per share, and updated its cash runway to extend into Q1 2029 following a $200.4 million public offering. The company also announced interim data from its ALPHA3 trial, showing 58.3% of patients on cema-cel achieved minimal residual disease clearance with a favorable safety profile. Additionally, Allogene terminated its exclusive licensing agreement with Overland in parts of Asia, simplifying its focus on wholly controlled programs.
Allogene Therapeutics: Q1 Earnings Snapshot
Allogene Therapeutics Inc. (ALLO) reported a first-quarter loss of $42.6 million, or 18 cents per share, which surpassed Wall Street expectations of a 19-cent loss per share. The company's shares closed at $2.33, a significant increase from $1.13 a year ago.
Allogene Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
Allogene Therapeutics, Inc. reported its earnings results for the first quarter ended March 31, 2026, showing a reduced net loss of $42.61 million compared to $59.73 million in the prior year. This translates to a basic and diluted loss per share from continuing operations of $0.18, an improvement from $0.28 a year ago. The company is actively expanding treatment trials and recently announced a public offering of common stock.
Allogene Therapeutics Reports First Quarter 2026 Financial Results and Business Update
Allogene Therapeutics reported its Q1 2026 financial results and provided business updates. The company announced positive interim futility analysis results from its pivotal Phase 2 ALPHA3 trial for cema-cel in large B-cell lymphoma, showing significant MRD clearance and a favorable safety profile. Allogene also provided an update on its Phase 1 RESOLUTION trial for ALLO-329 in autoimmune diseases, signaling clinical activity at early dose levels, and extended its cash runway into Q1 2029 following a recent public offering.
Allogene Therapeutics: Q1 Earnings Snapshot
Allogene Therapeutics Inc. (ALLO) reported a first-quarter loss of $42.6 million, or 18 cents per share, which surpassed Wall Street expectations. Analysts surveyed by Zacks Investment Research had predicted a loss of 19 cents per share. The company's shares were trading at $2.33, up from $1.13 a year ago.
Allogene Therapeutics Q1 2026 earnings preview
This article provides a Q1 2026 earnings preview for Allogene Therapeutics. It is a placeholder indicating that more detailed information about the company's financial performance will be available soon.
Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update
Allogene Therapeutics, Inc. announced it will report its first-quarter 2026 financial results and offer a business update on May 13, 2026, after market close. This will be followed by a live audio webcast and conference call for investors and the public. The company specializes in developing allogeneic CAR T products for cancer and autoimmune diseases.
Allogene schedules May 13 webcast for Q1 results and business update
Allogene Therapeutics (Nasdaq: ALLO) announced it will report its first-quarter 2026 financial results and provide a business update on May 13, 2026, after market close. A live audio webcast and conference call are scheduled for 2:00 p.m. PT / 5:00 p.m. ET, with a replay available for approximately 30 days. Investors can access the webcast via the company's website, and registered participants can receive a PIN to ask questions during the call.
Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update
Allogene Therapeutics, Inc. announced it will report its first-quarter 2026 financial results and provide a business update on May 13, 2026, after market close. This will be followed by a live audio webcast and conference call. The company specializes in developing allogeneic CAR T cell products for cancer and autoimmune disease.
Allogene Therapeutics ALPHA3 trial explores allogeneic CAR T potential in LBCL treatment
Allogene Therapeutics is advancing its allogeneic CAR T therapy through the ALPHA3 clinical trial, aiming to provide new treatment options for patients with large B-cell lymphoma (LBCL). This research, highlighted by Dr. Zachary Roberts, EVP of R&D and CMO, seeks to improve cell therapy outcomes for those with limited alternatives. The company is also diversifying its pipeline with therapies like ALLO-329 for autoimmune diseases, demonstrating a broader commitment to cell therapy innovation.
Allogene Therapeutics (ALLO) Closes $200.4M Public Offering of Common Stock
Allogene Therapeutics Inc. (NASDAQ: ALLO) successfully closed a public offering of common stock on April 16, raising $200.4 million in gross proceeds. The offering involved 87.5 million shares at $2.00 each, plus an additional 12.7 million shares from an underwriter option. The capital will be used for general corporate purposes, including clinical trials and R&D, to advance its CAR T-cell therapies.
Allogene Therapeutics spotlights CTO participation in cell therapy innovation forum
Allogene Therapeutics announced that its Chief Technology Officer, Ben Beneski, will participate in a panel discussion at an event hosted by Cancer Research, focusing on next-generation cell-based therapies. This participation highlights Allogene's commitment to innovation in the allogeneic and cell therapy sector. The company has also been active in significant developments, including launching a new CAR-T treatment for autoimmune diseases and discussing M&A strategies in allogeneic CAR T therapies.
[ARS] Allogene Therapeutics, Inc. SEC Filing
This article reports an ARS filing by Allogene Therapeutics, Inc. (ALLO) on April 30, 2026, which is classified as having a low filing impact and neutral sentiment. The document is available in PDF format. The company also recently announced a public offering of common stock and shared updates on its clinical trials and platform advancements.
Allogene (NASDAQ: ALLO) proxy backs share authorization boost and pay votes
Allogene Therapeutics is seeking shareholder approval for several key proposals at its virtual 2026 annual meeting on June 18, 2026. These include the election of three Class II directors, advisory votes on executive compensation and its frequency, and the ratification of Ernst & Young LLP as the independent auditor. Most notably, the company requests approval to amend its Certificate of Incorporation to double the authorized common stock from 400 million to 800 million shares, providing flexibility for future financial and strategic needs.
Allogene Therapeutics (ALLO) price target increased by 16.66% to 8.83
This article reports that the price target for Allogene Therapeutics (ALLO) has been increased by 16.66%, raising it to $8.83. This adjustment indicates a more optimistic outlook for the company's stock from the perspective of the analyst making the change.
ALLO stock hits 2-year highs – analyst calls Allogene’s phase 2 trial data to treat lymphoma a ‘home run’
Allogene Therapeutics' stock (ALLO) reached a two-year high following positive Phase 2 trial data for its lymphoma treatment. An analyst described the results as a "home run," indicating significant potential for the company's therapy. This news suggests a positive outlook for ALLO and its progress in developing innovative cancer treatments.
Allogene Therapeutics falls after trial delay, rating downgrade post Q1 results
Allogene Therapeutics experienced a stock decline following the announcement of a delay in its pivotal ALPHA2 trial for allogeneic CAR T therapy and a subsequent rating downgrade by William Blair. The delay is attributed to the need to incorporate new FDA guidance on the risks of secondary malignancies, pushing the trial's completion to 2027. Despite reporting positive preclinical data for ALLO-304 and solid financial results in Q1, the market reacted negatively to the trial delay.
Allogene Therapeutics unveils ALLO-329 to target autoimmune disease with allogeneic CAR-T approach
Allogene Therapeutics has introduced ALLO-329, an investigational allogeneic CAR-T therapy, to treat autoimmune diseases. This new therapy utilizes the company's Dagger technology to potentially reduce or eliminate the need for lymphodepletion, improving patient experience and access to CAR-T solutions. The company has previously released positive interim data from its ALPHA3 trial for LBCL treatment and new findings on dual CAR-T cells for multiple myeloma.
Allogene Therapeutics falls after trial delay, rating downgrade post Q1 results
Allogene Therapeutics (ALLO) shares fell following a delay in its global Phase 2/3 ALPHA2 trial and a subsequent rating downgrade from Evercore ISI. The trial's primary endpoint, which requires additional follow-up, is now expected by year-end 2026, delaying potential FDA approval. Despite this, some of its other drug candidates, particularly the ALLO-501A program, showed promising results, including an 88% overall response rate in its Phase 1 trial.
Allogene Therapeutics prices $175M stock offering at $2 per share
Allogene Therapeutics has priced a public offering of 87,500,000 shares of its common stock at $2.00 per share, aiming to raise $175 million before underwriting discounts and commissions. The offering is expected to close on April 30, 2026. The company's stock symbol is NASDAQ:ALLO.
Allogene Therapeutics aims to redefine CAR T therapy with scalable allogeneic approach
Allogene Therapeutics is focusing on developing scalable allogeneic CAR T cell therapies to address the limitations of existing autologous treatments. The company's goal is to make CAR T options faster, more efficient, and broadly accessible to a wider patient population. Recent interim ALPHA3 trial data shows early promise for their allogeneic approach in treating LBCL, indicating progress in their efforts to improve cell therapy accessibility.
Allogene Therapeutics announces public offering of $175M of common stock
Allogene Therapeutics has announced a public offering of $175 million of shares of its common stock. The biopharmaceutical company, focused on allogeneic CAR T (AlloCAR T™) products, stated that the offering is subject to market conditions. This move aims to raise capital, likely for its ongoing research and development efforts.
Allogene jumps on analysis of Phase 2 data for B-cell lymphoma asset cema-cel
Allogene Therapeutics' stock rose after an analyst reiterated a buy rating and $6 price target following an analysis of positive Phase 2 data for their B-cell lymphoma asset, cema-cel. The data suggests deep and durable responses, particularly in patients with aggressive disease who had received prior CAR T-cell therapy. The analyst anticipates that cema-cel could become a new standard of care for relapsed/refractory large B-cell lymphoma patients.
Allogene Therapeutics (NASDAQ:ALLO) SVP Annie Yoshiyama Sells 9,586 Shares
Allogene Therapeutics (NASDAQ:ALLO) SVP Annie Yoshiyama sold 9,586 shares of the company's stock on April 21st to cover tax withholding obligations, reducing her stake by 7.15%. The transaction, valued at $22,143.66, was disclosed through an SEC filing. Despite the sale, institutional investors maintain a significant ownership of 83.63%, and analysts currently rate the stock as a "Moderate Buy" with an average price target of $8.44.
[SCHEDULE 13G] Allogene Therapeutics, Inc. Passive Investment Disclosure (>5%)
Frazier-affiliated investors have filed a Schedule 13G for Allogene Therapeutics, Inc. (ALLO), reporting shared passive ownership stakes. Frazier Life Sciences Public Fund, L.P. holds 16,205,306 shares (4.7%), with several other affiliated Frazier funds holding additional positions, totalling over 5% collectively. The filing details the beneficial ownership, shared voting, and dispositive power, calculating percentages based on 243,777,920 outstanding shares as of March 10, 2026, and an additional 100,200,000 shares sold by the issuer on April 16, 2026.
Allogene (NASDAQ: ALLO) SVP sale covers RSU taxes, holds 124,517 shares
Allogene Therapeutics' SVP of Finance, Annie Yoshiyama, sold 9,586 shares of common stock at an average price of $2.31-$2.33 per share. This transaction was primarily to cover tax withholding obligations associated with the vesting of restricted stock units, as mandated by a "sell to cover" arrangement, not a discretionary trade. Following the sale, Yoshiyama directly holds 124,517 Allogene shares, which includes 3,781 shares acquired through an employee stock purchase program on March 15, 2026.
Allogene Therapeutics prices $175M stock offering at $2 per share
Allogene Therapeutics has priced a $175 million stock offering at $2 per share. The offering includes approximately 87.5 million shares of its common stock. This financial move aims to raise significant capital for the biotechnology company.
Allogene Therapeutics announces public offering of $175M of common stock
Allogene Therapeutics has announced a public offering of $175 million worth of its common stock. This move is likely intended to raise capital for the company's operations, research, and development efforts. Further details on the offering, such as pricing and terms, would typically be provided in subsequent announcements or filings.
Allogene Therapeutics VP joins FiercePharmaEngage to drive M and A strategies in allogeneic cell therapy
Allogene Therapeutics' VP of Corporate and Business Development, Daniel Hunt, is attending FiercePharmaEngage to discuss M&A strategies for allogeneic CAR T therapies. The company aims to use M&A to foster innovation, broaden access to cell therapy treatments, and build on its existing expertise. This move follows recent advancements in their CAR T therapy trials and innovation efforts.
Allogene Therapeutics (Nasdaq:ALLO) - Stock Analysis
This Simply Wall St analysis provides an overview of Allogene Therapeutics (ALLO), a clinical-stage immuno-oncology company. It highlights the company's valuation, future growth prospects, financial health, and recent news, noting that ALLO is trading significantly below its estimated fair value but faces risks like shareholder dilution and unprofitability. The report also details analyst price targets and narratives, along with stock performance and key company updates.
H.C. Wainwright Maintains Buy Rating on Allogene Therapeutics (ALLO)
H.C. Wainwright maintained a Buy rating on Allogene Therapeutics (ALLO) but lowered its price target to $11 from $12 following a common stock offering, viewing the recent share pullback as an attractive entry point. Meanwhile, Jefferies raised its price target to $10 from $6 and maintained a Buy rating after positive interim data from the Phase 2 ALPHA3 trial for cema-cel, showing promising results in large B-cell lymphoma. The therapy demonstrated good tolerability and significant improvements in MRD negativity and ctDNA levels compared to the observation arm.
Allogene Therapeutics Inc (ALLO) News, Articles, Events & Latest Updates
This page provides a compilation of recent news, articles, and updates related to Allogene Therapeutics Inc (ALLO). It includes financial data, stock performance metrics, and a feed of recent headlines concerning insider stock sales, analyst ratings, and trading activity for the company.
Allogene Therapeutics Expands Pivotal Phase 2 ALPHA3 Trial to South Korea and Australia
Allogene Therapeutics announced the expansion of its pivotal Phase 2 ALPHA3 study for cemacabtagene ansegedleucel (cema-cel) to South Korea and Australia. This expansion aims to leverage established clinical research infrastructures in these regions and follows positive interim futility analysis findings for cema-cel in large B-cell lymphoma. The study, which was already enrolling across North America, is now set to include over 80 global sites, with patient screening in the new regions expected to begin in Q2 2026.
Allogene (NASDAQ: ALLO) RSU vests 9,586 shares; Form 144 filed 04/21/2026
Allogene Therapeutics (NASDAQ: ALLO) filed a Form 144 reporting the vesting of 9,586 shares of Common Stock from a restricted stock unit (RSU) award on April 20, 2026. The filing indicates a routine insider compensation event and notifies the market of an intended sale by the recipient. Morgan Stanley Smith Barney LLC is listed as the broker/dealer for the potential sale.
Lymphoma trial expands to 80 sites as Allogene adds 2 countries
Allogene Therapeutics has expanded its pivotal Phase 2 ALPHA3 trial for cema-cel, a treatment for large B-cell lymphoma, to include South Korea and Australia, increasing global sites to over 80. The company anticipates screening and enrollment to begin in Q2 2026, aiming for approximately 220 patients by the end of 2027. Interim analysis showed favorable minimal residual disease clearance and a positive safety profile for cema-cel.
Allogene expands lymphoma trial to South Korea, Australia
Allogene Therapeutics Inc. has announced the expansion of its Phase 2 ALPHA3 study for large B-cell lymphoma to South Korea and Australia, increasing the global trial sites to over 80. The study, evaluating cema-cel as a first-line consolidation treatment, showed promising interim results with 58.3% minimal residual disease clearance and no serious treatment-related adverse events. This news follows recent positive developments, including a successful public offering and upgrades from various financial analysts.
Allogene Therapeutics Expands Pivotal Phase 2 ALPHA3 Trial to South Korea and Australia
Allogene Therapeutics has expanded its pivotal Phase 2 ALPHA3 trial for cemacabtagene ansegedleucel (cema-cel) to South Korea and Australia, adding to over 80 global sites. This expansion aims to support continued enrollment and global development of cema-cel, an investigational allogeneic CAR T product for large B-cell lymphoma. Interim futility analysis showed promising minimal residual disease (MRD) clearance with cema-cel, suggesting potential for an outpatient regimen.
Allogene Therapeutics Expands Pivotal Phase 2 ALPHA3 Trial to South Korea and Australia
Allogene Therapeutics has announced the expansion of its pivotal Phase 2 ALPHA3 trial for cemacabtagene ansegedleucel (cema-cel) to South Korea and Australia. This expansion aims to evaluate cema-cel as a first-line consolidation treatment for patients with large B-cell lymphoma (LBCL), increasing the global trial footprint to over 80 sites. The company reported promising interim futility analysis results showing cema-cel's effectiveness in minimal residual disease clearance and good tolerability.
Allogene Therapeutics Expands Pivotal Phase 2 ALPHA3 Trial to South Korea and Australia
Allogene Therapeutics is expanding its pivotal Phase 2 ALPHA3 trial for cemacabtagene ansegedleucel (cema-cel) to South Korea and Australia, adding to over 80 global sites. The trial evaluates cema-cel as a first-line consolidation treatment for patients with large B-cell lymphoma (LBCL). This expansion follows positive interim data showing significant minimal residual disease clearance with a favorable safety profile, and aims to support continued enrollment and global development of cema-cel.
